The NCCN Guidelines added BARD1 to their 2020 version stating that though there is a potential for increased risk for BC in female heterozygous carriers of BARD1 variants (risk not defined), though there is insufficient evidence to make recommendations (www.nccn.org). This evidence concerns the gene BARD1 and breast cancer.